Eisai's story revolves around Leqembi and Lenvima, with Leqembi launching in Japan. Margin of safety is quite apparent. Find ...

Eisai has entered into a license agreement with fellow Japanese drugmaker Sato Pharmaceutical regarding the development and commercialization rights for the antifungal agent fosravuconazole in the ...

More convenient Alzheimer's blood tests expected to be ready by 2025 could help Eisai reach a bigger share of China's estimated 17 million people with early-stage disease, a company spokesperson ...

Japanese pharma company Eisai (ESAIY) reported positive results in clinical trials of its Alzheimer’s drug Leqembi. This could mean a revolution for administering the drug, which is currently ...

Eisai said in a statement that it has set up a company-wide task force to mitigate the situation, and is working on recovery with its cybersecurity partners, as well as talking to law enforcement.

TOKYO -- Japanese pharmaceutical company Eisai is developing an Alzheimer's disease treatment that targets a protein linked ...

(RTTNews) - BioArctic AB's partner Eisai announced that Leqembi (generic name: lecanemab) has been approved for treatment of Alzheimer's disease or AD in Israel.

Eli Lilly's Kisunla secured standard approval from the U.S. Food and Drug Administration on Tuesday for slowing the ...

BioArctic AB's partner Eisai announced that the Department of Health in Hong Kong has approved Leqembi for treatment of Alzheimer's disease. Treatment with Leqembi should be initiated in patients with ...

Eli Lilly & Co.’s Alzheimer’s treatment was cleared in the US as the second drug to slow progression of the mind-robbing ...

If you suffered losses exceeding $100,000 in Biogen between February 3, 2022 and February 13, 2024 and would like to discuss ...

Eisai (OTCPK:ESALF) (OTCPK:ESAIY) has partnered with a major Chinese medical insurance company to offer an insurance plan specifically for Alzheimer's disease, including partial coverage of the ...